Published in J Clin Invest on February 01, 1989
Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella. J Clin Invest (1989) 1.47
Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology (2016) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Studies on gonococcus infection. XII. Colony color and opacity varienats of gonococci. Infect Immun (1978) 8.19
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Surface-exposed protein antigens of the gonococcal outer membrane. Infect Immun (1981) 3.28
Serogrouping of Neisseria gonorrhoeae: identification of four immunologically distinct acidic polysaccharides. J Infect Dis (1976) 2.87
Purification and radiolabeling of human C1q. J Immunol (1981) 2.75
Monoclonal antibody that recognizes an outer membrane antigen common to the pathogenic Neisseria species but not to most nonpathogenic Neisseria species. Infect Immun (1984) 2.65
Antigenic and physical diversity of Neisseria gonorrhoeae lipooligosaccharides. Infect Immun (1986) 2.55
Antigenicity of Neisseria gonorrhoeae outer membrane protein(s) III detected by immunoprecipitation and Western blot transfer with a monoclonal antibody. Infect Immun (1982) 2.48
The classical complement pathway: activation and regulation of the first complement component. Adv Immunol (1985) 2.38
The effect of protein II and pili on the interaction of Neisseria gonorrhoeae with human polymorphonuclear leucocytes. J Gen Microbiol (1986) 1.82
Variability of the lytic susceptibility of Neisseria gonorrhoeae to human sera. J Immunol (1977) 1.81
Gonococci possessing only certain P.II outer membrane proteins interact with human neutrophils. Infect Immun (1988) 1.79
Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. J Immunol (1974) 1.74
Physicochemical and functional characterization of the C1r subunit of the first complement component. J Immunol (1976) 1.67
Serum sensitivity of Neisseria gonorrhoeae: the role of lipopolysaccharide. J Infect Dis (1984) 1.64
Cloning of the structural genes of three H8 antigens and of protein III of Neisseria gonorrhoeae. J Exp Med (1986) 1.63
Surface peptide mapping of protein I and protein III of four strains of Neisseria gonorrhoeae. Infect Immun (1982) 1.52
Neisserial antigen H.8 is immunogenic in patients with disseminated gonococcal and meningococcal infections. J Infect Dis (1985) 1.43
Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun (1981) 1.43
Analyses of gonococcal H8 antigen. Surface location, inter- and intrastrain electrophoretic heterogeneity, and unusual two-dimensional electrophoretic characteristics. J Exp Med (1985) 1.40
Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. J Clin Invest (1985) 1.35
Serum bactericidal action and activation of the classic and alternate complement pathways by Neisseria gonorrhoeae. J Lab Clin Med (1978) 1.34
A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J Immunol (1982) 1.30
Bactericidal but not nonbactericidal C5b-9 is associated with distinctive outer membrane proteins in Neisseria gonorrhoeae. J Immunol (1985) 1.25
Activation of complement by serum-resistant Neisseria gonorrhoeae. Assembly of the membrane attack complex without subsequent cell death. J Exp Med (1982) 1.25
Antibody-independent interactions between Escherichia coli J5 and human complement components. J Immunol (1981) 1.23
Monoclonal antibodies directed against gonococcal protein I vary in bactericidal activity. J Immunol (1985) 1.22
Immunoglobulin class responsible for gonococcal bactericidal activity of normal human sera. J Immunol (1979) 1.18
Activation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of the classical and alternative pathways. Mol Immunol (1987) 1.16
Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism. J Immunol (1982) 1.15
Distribution of specific DNA sequences among pathogenic and commensal Neisseria species. Infect Immun (1987) 1.14
Antibody-independent activation of C1, the first component of complement, by cardiolipin. J Immunol (1985) 1.13
Localization of a conserved epitope and an azurin-like domain in the H.8 protein of pathogenic Neisseria. Mol Microbiol (1987) 1.08
Isolation and preliminary biochemical characterization of the gonococcal H.8 antigen. J Exp Med (1986) 1.00
Antibody-independent activation of the classical pathway of human serum complement by lipid A is restricted to re-chemotype lipopolysaccharide and purified lipid A. Infect Immun (1986) 0.99
Antibody-independent C1 activation by E. coli. J Immunol (1984) 0.98
Structure and activation of C1: current concepts. Complement (1984) 0.94
Mechanism of antibody-independent activation of the first component of complement (Cl) on retrovirus membranes. Biochemistry (1980) 0.90
Reconstitution of C1 in native proenzyme form and its use in a quantitative C1 activation test. J Immunol (1977) 0.89
The first component of human complement (C1): activation and control. Springer Semin Immunopathol (1983) 0.88
Antibody-independent interaction between the first component of human complement, C1, and the outer membrane of Escherichia coli D31 m4. Biochem J (1985) 0.86
Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement. J Immunol (1987) 0.80
Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1. J Immunol (1986) 0.80
Purification of C1 inhibitor. A new approach for the isolation of this biologically important plasma protease inhibitor. J Immunol Methods (1987) 0.78
Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol (1983) 25.26
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Monoclonal antibody against a genus-specific antigen of Chlamydia species: location of the epitope on chlamydial lipopolysaccharide. Infect Immun (1984) 4.53
Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med (1979) 4.52
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med (1996) 3.89
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. J Clin Invest (1972) 3.64
The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol (1974) 3.38
Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med (1976) 3.10
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med (1976) 2.96
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest (1972) 2.82
Purification and radiolabeling of human C1q. J Immunol (1981) 2.75
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
The parasitophorous vacuole membrane surrounding intracellular Toxoplasma gondii functions as a molecular sieve. Proc Natl Acad Sci U S A (1994) 2.70
A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol (1974) 2.60
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (1990) 2.49
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med (1983) 2.49
Bactericidal and opsonic properties of C4-deficient guinea pig serum. J Immunol (1972) 2.48
Lipopolysaccharide variation in Coxiella burnetti: intrastrain heterogeneity in structure and antigenicity. Infect Immun (1985) 2.47
A receptor for the third component of complement in the human renal glomerulus. J Exp Med (1975) 2.39
Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance. J Clin Invest (1988) 2.38
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
In vitro studies of complement function in sera of C4-deficient guinea pigs. J Exp Med (1971) 2.29
Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet (1981) 2.29
Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol (1986) 2.28
The Toxoplasma gondii rhoptry protein ROP 2 is inserted into the parasitophorous vacuole membrane, surrounding the intracellular parasite, and is exposed to the host cell cytoplasm. J Cell Biol (1994) 2.26
Nodular lymphoma--evidence for origin from follicular B lymphocytes. N Engl J Med (1974) 2.26
Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men. J Exp Med (1991) 2.22
The type I macrophage scavenger receptor binds to gram-positive bacteria and recognizes lipoteichoic acid. Proc Natl Acad Sci U S A (1994) 2.22
Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: studies in patients with dermatitis herpetiformis and normal subjects. N Engl J Med (1981) 2.19
Association of host cell endoplasmic reticulum and mitochondria with the Toxoplasma gondii parasitophorous vacuole membrane: a high affinity interaction. J Cell Sci (1997) 2.16
Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathog (1987) 2.15
The effect of temperature on the reactivity of guinea-pig complement with gamma G and gamma M haemolytic antibodies. Immunology (1970) 2.14
Characterization of C1q receptor expression on human phagocytic cells: effects of PDBu and fMLP. J Immunol (1986) 2.09
Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore) (1977) 2.07
Safe haven: the cell biology of nonfusogenic pathogen vacuoles. Annu Rev Microbiol (1997) 2.07
The localization of non-microbial antigens in the draining lymph nodes of tolerant, normal and primed rabbits. Immunology (1967) 2.07
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 2.05
Ontogeny of B lymphocytes. II. Relative rates of appearance of lymphocytes bearing surface immunoglobulin and complement receptors. J Exp Med (1974) 2.03
Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci U S A (1981) 2.02
Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA). J Immunol (1979) 2.01
In vivo studies in C4-deficient guinea pigs. J Exp Med (1971) 2.00
Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. J Cell Biol (2000) 1.96
Lipopolysaccharide size and distribution determine serum resistance in Salmonella montevideo. J Bacteriol (1987) 1.93
Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol (1984) 1.87
The critical role of complement in experimental pneumococcal sepsis. J Infect Dis (1980) 1.87
C3 binds preferentially to long-chain lipopolysaccharide during alternative pathway activation by Salmonella montevideo. J Immunol (1986) 1.82
Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest (1972) 1.82
Complement depletion in cryptococcal sepsis. J Immunol (1978) 1.82
Lipopolysaccharide nomenclature--past, present, and future. J Bacteriol (1986) 1.80
The complement system in host defense and inflammation. Rev Infect Dis (1980) 1.80
NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann Intern Med (1983) 1.79
Kinetics and pattern of organelle exocytosis during Toxoplasma gondii/host-cell interaction. Parasitol Res (1993) 1.76
A new complement-mediated cytolytic mechanism--the C1-bypass activation pathway. Proc Natl Acad Sci U S A (1973) 1.74
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med (1984) 1.74
Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med (1972) 1.73
Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5. J Immunol (1974) 1.73
The parasitophorous vacuole membrane surrounding Plasmodium and Toxoplasma: an unusual compartment in infected cells. J Cell Sci (1998) 1.73
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol (1986) 1.72
CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J Immunol (1989) 1.72
The Toxoplasma gondii protein ROP2 mediates host organelle association with the parasitophorous vacuole membrane. J Cell Biol (2001) 1.69
Increased ion permeability of planar lipid bilayer membranes after treatment with the C5b-9 cytolytic attack mechanism of complement. Proc Natl Acad Sci U S A (1976) 1.69
C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med (1988) 1.67
Arrangement of pili in colonies of Neisseria gonorrhoeae. J Bacteriol (1984) 1.66
Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol (2001) 1.66
Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med (1981) 1.65
Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science (1999) 1.65
Hereditary deficiency of the sixth component of complement in man. I. Immunochemical, biologic, and family studies. J Clin Invest (1974) 1.65
The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis (1983) 1.63
Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption. Mol Microbiol (1993) 1.63
The subunits in rabbit anti-Forssman IgM antibody. J Exp Med (1968) 1.60
A simple method for the determination of complement receptor-bearing mononuclear cells. J Immunol (1976) 1.59
Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun (2001) 1.59
The effect of Bacillus Calmette-Guerin-induced macrophage activation on the in vivo clearance of sensitized erythrocytes. J Clin Invest (1974) 1.58
Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. J Clin Invest (1979) 1.58
cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity (1997) 1.58
Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore) (1979) 1.57
Lack of binding of human C3, in its native state, to C3b receptors. J Immunol (1981) 1.57
Targeting to rhoptry organelles of Toxoplasma gondii involves evolutionarily conserved mechanisms. Nat Cell Biol (2000) 1.57